...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Cancer >The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer
【24h】

The relationship between glasgow prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer

机译：晚期非小细胞肺癌患者格拉斯哥预后评分与血清肿瘤标志物的关系

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Glasgow Prognostic Score (GPS) has been reported as a powerful prognostic tool for patients with advanced non–small cell lung cancer (NSCLC). The aim of this study was to assess the relationship between GPS and prognosis related tumor markers in patients with advanced NSCLC. Methods We included 138 advanced NSCLC patients and twenty healthy controls in the study. GPS was calculated by combined serum C-reactive protein (CRP) and albumin. Three serum tumor markers, which included cytokeratin 19 fragment antigen 21-1 (CYFRA21–1), carcinoembryonic antigen (CEA) and tissue polypeptide specific antigen (TPS), were detected by enzyme-linked immunosorbent assay (ELISA). GPS and tumor markers were all assessed before chemotherapy. All patients received at least 2 courses of cisplatin-based chemotherapy. After that, 2 to 5?years follow-up was conducted. Results Median levels of CYFRA21–1 were 1.5?ng/ml (0.1–3.1?ng/ml) in healthy controls, and 4.6?ng/ml (0.7–35.2?ng/ml) in GPS 0 advanced NSCLC, 11.2?ng/ml (0.4–89.2) ng/ml in GPS 1 advanced NSCLC, and 15.7?ng/ml (2.9–134.6?ng/ml) in GPS 2 advanced NSCLC, respectively. Median levels of CYFRA21-1 were higher in NSCLC patients than in healthy controls, and CYFRA21-1 increased gradually according to GPS category in NSCLC patients ( P 3.3?ng/ml) and TPS (>80 U/l) were related with the prognosis of advanced NSCLC by univariate analyses, but multivariate analyses showed CYFRA21-1, TPS and CEA were not the independent prognostic factors for advanced NSCLC. Conclusions Our results showed GPS were positive correlated with CYFRA21-1, CEA and TPS in patients with advanced NSCLC. However, GPS was more efficient in predicting prognosis of advanced NSCLC than these three single prognosis related tumor markers.
机译：背景格拉斯哥预后评分（GPS）被报告为晚期非小细胞肺癌（NSCLC）患者的强大预后工具。这项研究的目的是评估GPS与晚期NSCLC患者预后相关的肿瘤标志物之间的关系。方法我们纳入了138位晚期NSCLC患者和20位健康对照。通过结合血清C反应蛋白（CRP）和白蛋白计算GPS。通过酶联免疫吸附测定（ELISA）检测了三种血清肿瘤标志物，包括细胞角蛋白19片段抗原21-1（CYFRA21-1），癌胚抗原（CEA）和组织多肽特异性抗原（TPS）。化疗前对GPS和肿瘤标志物进行了评估。所有患者均接受了至少2个疗程的基于顺铂的化疗。之后，进行2至5年的随访。结果健康对照组中CYFRA21-1的中位数水平为1.5？ng / ml（0.1–3.1？ng / ml），GPS 0晚期NSCLC，11.2？ng中位数为4.6？ng / ml（0.7–35.2？ng / ml）。在GPS 1高级NSCLC中为/ ml（0.4–89.2）ng / ml，在GPS 2高级NSCLC中分别为15.7？ng / ml（2.9–134.6？ng / ml）。 NSCLC患者中CYFRA21-1的中位数水平高于健康对照组，并且CYFRA21-1根据GPS类别逐渐升高（NSCLC患者（P 3.3？ng / ml）和TPS（> 80 U / l）与糖尿病患者相关。单因素分析对晚期NSCLC的预后，但多因素分析显示CYFRA21-1，TPS和CEA不是晚期NSCLC的独立预后因素。结论我们的研究结果表明，晚期NSCLC患者的GPS与CYFRA21-1，CEA和TPS呈正相关。但是，GPS在预测晚期NSCLC的预后方面比这三个与预后有关的肿瘤标记更为有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号